OS Therapies Incorporated (OSTX)
NYSEAMERICAN: OSTX · Real-Time Price · USD
1.780
-0.070 (-3.78%)
Jun 5, 2026, 4:00 PM EDT - Market closed
OS Therapies Earnings Call Transcripts
Fiscal Year 2025
-
A novel Listeria-based immunotherapy platform is advancing toward regulatory approval for pediatric osteosarcoma, with strong phase II-B results and alignment with US, UK, and EU agencies. The company anticipates significant value from a Priority Review Voucher and is expanding into animal health and additional cancer indications.